## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.14 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($200.97)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. J&J Wins Proactive FDA National Priority Voucher for Multiple Myeloma Combo**
- Source: BioSpace | 20251216T130832 | Bullish | Relevance: 100%
- Johnson & Johnson has been proactively awarded a Commissioner’s National Priority Voucher by the FDA for its investigational combination of Tecvayli plus Darzalex for relapsed or refractory multiple myeloma. This unusual award was based on impressive Phase III MajesTEC-3 study results, showing significant improvements in progression-free and overall survival. The voucher will drastically shorten the drug's review time, highlighting the FDA's new mission to accelerate promising therapies.

**2. J&J claims FDA's latest national priority voucher**
- Source: pharmaphorum | 20251216T100812 | Bullish | Relevance: 100%
- The FDA has awarded Johnson & Johnson a Commissioner's National Priority Voucher (CNPV) for a combination regimen utilizing Tecvayli and Darzalex Faspro for multiple myeloma. This expedited approval, part of a controversial pilot program, was based on significant improvements in progression-free and overall survival shown in the MajesTEC-3 study. The CNPV program aims to accelerate the availability of important new therapies, though it has faced criticism regarding its selection process and transparency.

**3. Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open**
- Source: ts2.tech | 20251216T020756 | Somewhat-Bullish | Relevance: 100%
- Johnson & Johnson (NYSE: JNJ) shares saw modest gains in after-hours trading on December 15, 2025, driven by the FDA awarding a national priority voucher for its multiple myeloma drug, teclistamab. The voucher, part of a pilot program to accelerate reviews for national health priorities, highlights strong clinical data from the MajesTEC-3 study. Despite this positive catalyst, litigation related to talc verdicts remains an ongoing concern for the company, and investors are advised to watch for Tuesday's macro economic data releases.

**4. Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting (NYSE:JNJ)**
- Source: Seeking Alpha | 20251216T090813 | Somewhat-Bearish | Relevance: 100%
- Johnson & Johnson's stock is up significantly in 2025, reflecting solid execution and financial performance. However, current valuations are limiting further upside, as modest organic growth and margin expansion are offset by FX and portfolio actions rather than core improvements. The article maintains a strong Hold rating, pending a valuation pullback or clearer evidence of new growth drivers and margin expansion.

**5. FDA initiates priority voucher for J&J’s ‘Tec-Dara’ combo**
- Source: STAT | 20251216T030824 | Somewhat-Bullish | Relevance: 100%
- The FDA has initiated a priority review voucher for Johnson & Johnson's 'Tec-Dara' combination therapy, as reported in The Readout newsletter by Elaine Chen. This article also covers other biotech news, but is primarily exclusive content for STAT+ subscribers, requiring a subscription to read fully.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |
| 2025-12-11 | Citigroup | $232 | $215 | +8% |
| 2025-12-11 | RBC Capital | $230 | $209 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-11 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.14 suggests fair value with growth premium. Forward P/E 18.1x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (6 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $501.9B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.14 |
| Forward P/E | 18.1 |
| Current P/E | 19.2 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.5% to 1.8% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.77% (CS: 57) | Neutral |
| RSI_14 | 59.5 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.210x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $208.33
- **Stop Loss:** $200.97 (3.5% risk)
- **Target:** $223.05 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 129
- **Position Value:** $26,874.57
- **Portfolio %:** 26.87%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*